Clinical Trial Detail

NCT ID NCT03625505
Title A Study to Assess Safety and Efficacy of Venetoclax in Combination With Gilteritinib in Subjects With Relapsed/Refractory Acute Myeloid Leukemia
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors AbbVie
Indications

acute myeloid leukemia

Therapies

Gilteritinib + Venetoclax

Age Groups: adult senior

Additional content available in CKB BOOST